Xarelto Tablet, Film Coated
Product Images NDC 50090-4468

34 FDA label images from A-s Medication Solutions · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 34 technical images submitted to the FDA as part of the official labeling for Xarelto (NDC 50090-4468). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Xarelto 01)

Figure 1 (Xarelto 01)
A forest plot chart comparing the hazard ratio and 95% confidence intervals for rivaroxaban versus warfarin across various patient subgroups. Categories include prior warfarin use, age ranges, gender, weight, prior stroke/TIA, diabetic status, CHADS2 score, creatinine clearance levels, geographic region, and aspirin use at randomization. The chart visually depicts whether each subgroup favors rivaroxaban or warfarin based on the hazard ratio values.*
FDA Label Image

Chemical Structure (Xarelto 02)

Chemical Structure (Xarelto 02)
A forest plot comparing the risk of major bleeding with Xarelto plus aspirin versus aspirin alone across various subgroups including age, sex, region, weight, kidney function (eGFR), medical history, and comorbidities. The plot shows hazard ratios with 95% confidence intervals for each subgroup, indicating relative risk differences between treatment groups.*
FDA Label Image

Figure 2 (Xarelto 03)

Figure 2 (Xarelto 03)
Chemical structure of rivaroxaban, the active ingredient in Xarelto 20 mg film-coated tablets. The diagram shows the molecular arrangement with rings and functional groups characteristic of rivaroxaban.*
FDA Label Image

Figure 3 (Xarelto 04)

Figure 3 (Xarelto 04)
A pharmacokinetic (PK) fold change chart displaying Cmax and AUC values with 90% confidence intervals for different population groups relative to a reference. Groups include End-Stage Renal Disease (postdialysis/normal), varying degrees of Renal Impairment (severe, moderate, mild), Age (75-83 years vs 18-43 years), Body Weight categories (<=50 kg, >120 kg compared to 70-80 kg), and Hepatic Impairment (moderate and mild versus normal). The x-axis shows change relative to reference.*
FDA Label Image

Figure 4 (Xarelto 05)

Figure 4 (Xarelto 05)
A pharmacokinetic chart depicting fold change and 90% confidence intervals for various interacting drugs on rivaroxaban's Cmax and AUC. The graph includes combined P-gp and strong or moderate CYP3A inhibitors and inducers, as well as other drugs like aspirin, atorvastatin, clopidogrel, digoxin, and warfarin, showing their relative changes compared to rivaroxaban alone.*
FDA Label Image

Figure 5 (Xarelto 06)

Figure 5 (Xarelto 06)
A Kaplan-Meier curve chart comparing cumulative event rates over time between Xarelto and Warfarin. The x-axis shows days from randomization up to 900 days, and the y-axis shows cumulative event rates in percentage. The chart includes the number of subjects at risk for both groups at various time points and reports a hazard ratio (HR) with 95% confidence interval (CI).*
FDA Label Image

Figure 6 (Xarelto 07)

Figure 6 (Xarelto 07)
A forest plot comparing hazard ratios with 95% confidence intervals for rivaroxaban versus warfarin across various patient subgroups, including age, gender, weight, prior stroke/TIA, diabetic status, CHA2DS2 score, kidney function, geographic region, and ASA use at randomization. The plot visually displays the favorability of each drug within these categories.*
FDA Label Image

Figure 7 (Xarelto 08)

Figure 7 (Xarelto 08)
A line graph comparing cumulative event rates (%) over days from randomization for Xarelto (rivaroxaban) and Enoxaparin/VKA. The x-axis shows days up to 360, and the y-axis shows cumulative event rate up to 4%. Xarelto's event rate line is lower than Enoxaparin/VKA's throughout the study period, with patient risk numbers noted below the graph.*
FDA Label Image

Figure 8 (Xarelto 09)

Figure 8 (Xarelto 09)
A cumulative event rate line graph comparing Xarelto (rivaroxaban) with Enoxaparin/VKA over 360 days from randomization. The y-axis shows cumulative event rate percentage, and the x-axis shows time in days. The graph includes patient numbers at risk for both drugs at various timepoints and a hazard ratio (HR) with 95% confidence interval.*
FDA Label Image

Figure 9 (Xarelto 10)

Figure 9 (Xarelto 10)
A Kaplan-Meier cumulative event rate plot comparing Xarelto and Aspirin over 367 days from randomization. The y-axis shows cumulative event rate percentage, while the x-axis shows days from randomization. Xarelto's curve shows a lower event rate than Aspirin's. The chart includes numbers of subjects at risk for each treatment group over time and a hazard ratio with confidence interval.*
FDA Label Image

Figure 10 (Xarelto 11)

Figure 10 (Xarelto 11)
A forest plot chart comparing the primary efficacy outcomes of Xarelto plus aspirin versus aspirin alone in various patient subgroups, including age, sex, region, weight, kidney function (eGFR), myocardial infarction history, stroke history, prior heart failure, diabetes, coronary artery disease (CAD), and peripheral artery disease (PAD). The horizontal axis shows hazard ratios with confidence intervals, indicating whether outcomes favor Xarelto or aspirin.*
FDA Label Image

Figure 11 (Xarelto 12)

Figure 11 (Xarelto 12)
A line graph comparing the cumulative probability (%) of an event over time in days from randomization for two groups: Xarelto plus aspirin versus aspirin alone. The graph includes a hazard ratio comparison (0.76 with 95% confidence interval 0.66 to 0.86) indicating the relative risk between the two treatments. The number of subjects at risk at various time points is displayed below the x-axis for both groups.*
FDA Label Image

Figure 12 (Xarelto 13)

Figure 12 (Xarelto 13)
A forest plot chart comparing the primary efficacy outcome of Xarelto (rivaroxaban) versus placebo across different subgroups including age, sex, weight, eGFR, baseline diabetes, CAD, randomization strata, clopidogrel use, history of revascularization, and critical limb ischemia categories. The chart includes hazard ratios (HR) with 95% confidence intervals, displaying results favoring Xarelto or placebo along a horizontal axis from 0.5 to 2.*
FDA Label Image

Image (Xarelto 14)

Image (Xarelto 14)
A vertical color-coded chart on a syringe-like tool displaying glucose concentration levels in mmol/L from 0.5 up to 3.0. The chart includes various colored bands representing different glucose levels for visual reference.*
FDA Label Image

Image (Xarelto 15)

FDA Label Image

Image (Xarelto 16)

Image (Xarelto 16)
An illustration of a graduated oral dosing syringe filled with purple liquid, marked with measurement graduations from 0.5 mL to 5 mL for precise liquid volume measurement.*
FDA Label Image

Image (Xarelto 17)

Image (Xarelto 17)
An illustration of a syringe-like device with color-coded measurement markings along its body. Labels indicate the 'Tip' at the top and the 'Plunger' at the bottom. The device is primarily purple with various colored bands for dosing measurements.*
FDA Label Image

Image (Xarelto 18)

Image (Xarelto 18)
An illustration showing a bottle with a brown glass body and two components labeled: a white screw-on cap and a bottle adaptor underneath the cap. The image includes a warning in red text advising not to remove the bottle adaptor. This diagram is likely intended to instruct proper bottle assembly or usage.*
FDA Label Image

Image (Xarelto 19)

Image (Xarelto 19)
Instructional illustration showing a medication bottle with a label area highlighted, indicating where to check the "Discard after" date on the bottle for proper usage guidance. No specific drug information visible in the image.*
FDA Label Image

Image (Xarelto 20)

Image (Xarelto 20)
Illustration showing a handwashing procedure with water pouring onto hands, with soap bubbles depicted between the hands to indicate cleaning action.*
FDA Label Image

Image (Xarelto 21)

Image (Xarelto 21)
An illustration showing a hand holding and shaking a bottle with the word "SLOW!" in blue text to emphasize gentle shaking. The image likely demonstrates proper handling or mixing instructions for a liquid medication.*
FDA Label Image

Image (Xarelto 22)

Image (Xarelto 22)
An instructional illustration showing a side view of a bottle with a magnified section indicated by a circle and an arrow from an eye symbol, suggesting a close visual inspection of the bottle's content or label.*
FDA Label Image

Image (Xarelto 23)

Image (Xarelto 23)
A vertical syringe illustration showing volume markings in milliliters from 0.8 mL up to 5 mL. Different colored bands at specific volume levels are displayed inside the barrel, likely indicating measurement gradations or dosing information.*
FDA Label Image

Image (Xarelto 24)

Image (Xarelto 24)
A table listing dose volumes and their corresponding measures in milliliters (mL). The doses 7.5 mL, 10 mL, 15 mL, and 20 mL are shown with sums of 5 mL increments to achieve each total volume.*
FDA Label Image

Image (Xarelto 25)

Image (Xarelto 25)
An instructional illustration showing a hand holding a small vial with a purple cap being removed by pulling upwards, indicated by a blue arrow. The vial is magnified in an inset circle to highlight the cap detail.*
FDA Label Image

Image (Xarelto 26)

Image (Xarelto 26)
An instructional illustration showing hands placing a bottle adaptor onto a bottle opening. One hand holds the bottle upright while the other inserts the adaptor from above. The bottle cap is placed beside the bottle.*
FDA Label Image

Image (Xarelto 27)

Image (Xarelto 27)
An instructional diagram showing a hand holding a syringe vertically with the plunger being pushed downward by the other hand, indicated by a blue downward arrow. The image demonstrates proper technique for administering or preparing an injection.*
FDA Label Image

Image (Xarelto 28)

FDA Label Image

Image (Xarelto 29)

Image (Xarelto 29)
An instructional illustration showing a person pressing a button or area on a device shaft, with a close-up inset highlighting small round particles on the device. This diagram likely demonstrates a step in device preparation or activation.*
FDA Label Image

Image (Xarelto 30)

Image (Xarelto 30)
An instructional illustration showing a hand pressing the plunger of a syringe while holding the syringe barrel with the other hand. A blue upward arrow below the syringe indicates the direction of plunger movement.*
FDA Label Image

Image (Xarelto 31)

Image (Xarelto 31)
An instructional illustration showing a hand holding a bottle and another hand inserting or removing a dropper or similar device, indicated by a blue arrow pointing upward. The image appears to demonstrate a step in handling or preparing a liquid medication container.*
FDA Label Image

Image (Xarelto 32)

Image (Xarelto 32)
An instructional illustration showing a person administering medication into a child's mouth using an oral syringe placed at the side of the mouth.*
FDA Label Image

Image (Xarelto 33)

Image (Xarelto 33)
An instructional illustration showing two hands: one holding a small syringe-like device and the other holding a purple cylindrical container under a shower of water droplets falling from above. The image suggests rinsing or washing the container using water.*
FDA Label Image

Label Image (Lbl500904468)

Label Image (Lbl500904468)
Xarelto 20 mg film-coated tablets packaging label from A-S Medication Solutions. The label states each tablet contains 20 mg of rivaroxaban, with a total count of 90 tablets per package. Storage instructions note to keep the product at 77 degrees Fahrenheit or room temperature. The label also includes NDC 50090-4468-0 and a barcode with additional dosage packaging information.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.